Pregnancy outcomes among women with type 1 diabetes mellitus using continuous subcutaneous insulin infusion versus multiple daily injections: A retrospective cohort study
Restricted accessResearch articleFirst published online September, 2019
Pregnancy outcomes among women with type 1 diabetes mellitus using continuous subcutaneous insulin infusion versus multiple daily injections: A retrospective cohort study
Insulin delivery options for pregnant women with type 1 diabetes mellitus are either continuous subcutaneous insulin infusion or multiple daily injections. The aim of this paper is to compare pregnancy outcomes in women with type 1 diabetes mellitus using continuous subcutaneous insulin infusion or multiple daily injections in pregnancy.
Methods
Retrospective single-centre cohort study of 298 pregnancies booked between 2006 and 2016. Descriptive analysis was performed for HbA1c values. Logistic regression models were created to compare selected maternal and neonatal outcomes.
Results
Continuous subcutaneous insulin infusion was associated with increased risk of large-for-gestational age (aOR 2.00, 95% CI 1.20–3.34) and preterm neonates (aOR 1.80, 95% CI 1.04–3.03). Continuous subcutaneous insulin infusion had no association with increased risk of adverse pregnancy outcomes. No difference in HbA1c values existed between groups.
Conclusion
Using continuous subcutaneous insulin infusion for type 1 diabetes mellitus through pregnancy is associated with increased risk of large-for-gestational age and preterm neonates, without increased risk of associated adverse maternal or neonatal outcomes.
DreverEFeigDS.Novel insulin delivery technologies in women with pregestational type 1 diabetes: a review of the literature. Obstet Med2013;
6: 8–12.
3.
MissoMLEgbertsKJPageM, et al.
Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database System Rev2010; Cd005103.
4.
MukhopadhyayAFarrellTFraserRB, et al.
Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol2007;
197: 447–456.
5.
FarrarDTuffnellDJWestJ, et al.
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database System Rev2016; Cd005542.
6.
EganAMGaljaardSMareshMJA, et al.
A core outcome set for studies evaluating the effectiveness of prepregnancy care for women with pregestational diabetes. Diabetologia2017;
60: 1190–1196.
7.
DobbinsTASullivanEARobertsCL, et al.
Australian national birthweight percentiles by sex and gestational age, 1998–2007. Med J Aust2012;
197: 291–294.
8.
SterneJACWhiteIRCarlinJB, et al.
Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ2009;
338: b2393.
9.
JanssenKJMDondersARTHarrellFE, et al.
Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol2010;
63: 721–727.
10.
Wender-OzegowskaEZawiejskaAOzegowskaK, et al.
Multiple daily injections of insulin versus continuous subcutaneous insulin infusion for pregnant women with type 1 diabetes. Aust N Z J Obstet Gynaecol2013;
53: 130–135.
11.
KekalainenPJuutiMWalleT, et al.
Continuous subcutaneous insulin infusion during pregnancy in women with complicated type 1 diabetes is associated with better glycemic control but not with improvement in pregnancy outcomes.Diabetes Technol Ther2016;
18: 144–150.
12.
MurphyHRBellRCartwrightC, et al.
Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. Diabetologia2017;
60: 1668–1677.
13.
MiddletonPCrowtherCASimmondsL.Different intensities of glycaemic control for pregnant women with pre-existing diabetes. Cochrane Database System Rev2016;
5: Cd008540.
14.
The Diabetes Control Complications Trial Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol1996; 174: 1343–1353.
15.
CheungNWConnJJD’emdenMC, et al.
Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust2009;
191: 339–344.
16.
EversIMDe ValkHWVisserGH.Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ2004;
328: 915.
17.
FeldmanAZBrownFM.Management of type 1 diabetes in pregnancy. Curr Diab Rep2016;
16: 76.
18.
StarikovRSInmanKChienEK, et al.
Can hemoglobin A1c in early pregnancy predict adverse pregnancy outcomes in diabetic patients?J Diabetes Complications2014;
28: 203–207.
19.
CyganekKSkupienJKatraB, et al.
Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control. Endocrine2017;
55: 447–455.
20.
MorrensAVerhaegheJVanholeC, et al.
Risk factors for large-for-gestational age infants in pregnant women with type 1 diabetes. BMC Pregnancy Childbirth2016;
16: 162.
21.
RanasinghePDMaruthurNMNicholsonWK, et al.
Comparative effectiveness of continuous subcutaneous insulin infusion using insulin analogs and multiple daily injections in pregnant women with diabetes mellitus: a systematic review and meta-analysis. J Womens Health2015;
24: 237–249.
22.
NeffKJFordeRGavinC, et al.
Pre-pregnancy care and pregnancy outcomes in type 1 diabetes mellitus: a comparison of continuous subcutaneous insulin infusion and multiple daily injection therapy. Ir J Med Sci2014;
183: 397–403.
23.
EversIMDe ValkHWMolBW, et al.
Macrosomia despite good glycaemic control in type I diabetic pregnancy; results of a nationwide study in The Netherlands. Diabetologia2002;
45: 1484–1489.
24.
LoweWLBainJRNodzenskiM, et al.
Maternal BMI and glycemia impact the fetal metabolome. Diabetes Care2017;
40: 902–910.
25.
FreinkelN.Banting Lecture 1980. Of pregnancy and progeny. Diabetes1980;
29: 1023–1035.
26.
LawGREllisonGTHSecherAL, et al.
Analysis of continuous glucose monitoring in pregnant women with diabetes: distinct temporal patterns of glucose associated with large-for-gestational-age infants. Diabetes Care2015;
38: 1319–1325.
27.
FeigDSDonovanLECorcoyR, et al.
Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet2017;
390: 2347–2359.
28.
AbellSKSuenMPeaseA, et al.
Pregnancy outcomes and insulin requirements in women with type 1 diabetes treated with continuous subcutaneous insulin infusion and multiple daily injections: cohort study. Diabetes Technol Ther2017;
19: 280–287.
29.
Diabetes in pregnancy: management from preconception to the postnatal period: NICE guideline, NICE guideline (NG3). National Institute for Health and Care Excellence. 2015. Available at: https://www.nice.org.uk/guidance/ng3.
30.
PerssonMPasupathyDHansonU, et al.
Disproportionate body composition and perinatal outcome in large-for-gestational-age infants to mothers with type 1 diabetes. BJOG2012;
119: 565–572.
31.
CyganekKHebda-SzydloAKatraB, et al.
Glycemic control and selected pregnancy outcomes in type 1 diabetes women on continuous subcutaneous insulin infusion and multiple daily injections: the significance of pregnancy planning. Diabetes Technol Ther2010;
12: 41–47.
32.
HendersonJTWhitlockEPO’ConnorE, et al.
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med2014;
160: 695–703.
33.
CumminsERoylePSnaithA, et al.
Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess2010;
14: iii–iv,xi–xvi,1–181.
34.
RozeSSmith-PalmerJValentineW, et al.
Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review. Diabet Med2015;
32: 1415–1424.
